Although there was no apparent correlation between levels of phosphorylated MEK and phosphorylated ERK in these samples and cell lines, detectable levels of both phosphorylated MEK and ERK suggested activity of this pathway in neuroblastoma tumor cells and also suggested the potential efficacy of MEK inhibitors in neuroblastoma preclinical models. The gene discussed is MAP2K7; the disease is neoplasm.